Comparison of PNF and Non-Immersive Virtual Reality-Assisted PNF Exercises in Individuals With Adhesive Capsulitis

November 11, 2026 updated by: Mehmet CANLI, Kirsehir Ahi Evran Universitesi

Comparison of the Effects of Proprioceptive Neuromuscular Facilitation Exercises and Non-Immersive Virtual Reality-Assisted Proprioceptive Neuromuscular Facilitation Exercises Added to Conventional Physiotherapy in Individuals With Adhesive Capsulitis: A Randomized Controlled Trial

his study aims to compare the effects of conventional physiotherapy combined with Proprioceptive Neuromuscular Facilitation (PNF) exercises and conventional physiotherapy combined with non-immersive virtual reality-assisted PNF exercises in individuals with adhesive capsulitis (frozen shoulder).

A total of 60 individuals aged 40-65 years who have been diagnosed with adhesive capsulitis will participate in this randomized controlled trial. Participants will be randomly assigned to one of two groups. The first group will receive conventional physiotherapy combined with traditional PNF exercises, while the second group will receive conventional physiotherapy combined with non-immersive virtual reality-assisted PNF exercises.

Both groups will receive treatment three times per week for six weeks, for a total of 18 sessions. Each session will last 60 minutes, including 45 minutes of conventional physiotherapy and 15 minutes of either traditional PNF exercises or virtual reality-assisted PNF exercises.

Participants will be evaluated before treatment and immediately after the six-week intervention. The assessments will examine pain intensity, pain catastrophizing, fear of movement (kinesiophobia), upper extremity function, and shoulder-specific pain and disability.

The study aims to determine whether non-immersive virtual reality-assisted PNF exercises provide additional benefits compared with traditional PNF exercises when combined with conventional physiotherapy in individuals with adhesive capsulitis.

Study Overview

Detailed Description

Adhesive capsulitis is a musculoskeletal condition characterized by shoulder pain, progressive restriction of active and passive range of motion, and limitations in daily activities. Although conventional physiotherapy is commonly used to improve pain and shoulder function, additional rehabilitation approaches may provide further benefits.

Proprioceptive Neuromuscular Facilitation (PNF) is a therapeutic exercise approach involving spiral and diagonal movement patterns designed to improve neuromuscular control, coordination, and functional movement. Non-immersive virtual reality-assisted rehabilitation allows individuals to perform therapeutic movements in an interactive digital environment while receiving real-time visual feedback.

This study is designed as a two-arm, parallel-group, randomized controlled trial to investigate whether integrating non-immersive virtual reality into PNF exercises provides additional clinical and psychosocial benefits compared with traditional PNF exercises in individuals with adhesive capsulitis.

The interventions will incorporate upper extremity PNF diagonal movement patterns. In the traditional PNF group, these movements will be performed under the guidance of a physiotherapist using established PNF techniques. In the virtual reality-assisted PNF group, corresponding movement patterns will be performed through an interactive screen-based system that tracks upper extremity movements and provides real-time visual feedback.

The study will examine changes in pain intensity, pain catastrophizing, kinesiophobia, upper extremity function, and shoulder-specific pain and disability. Outcomes will be assessed using the Visual Analog Scale (VAS), Pain Catastrophizing Scale (PCS), Tampa Scale for Kinesiophobia (TSK), Disabilities of the Arm, Shoulder and Hand Questionnaire (DASH), and Shoulder Pain and Disability Index (SPADI).

By comparing these approaches, the study seeks to determine the potential contribution of non-immersive virtual reality to PNF-based rehabilitation and provide evidence regarding its clinical applicability in individuals with adhesive capsulitis.

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

Individuals aged 40-65 years.

Diagnosis of adhesive capsulitis confirmed by a specialist physician.

Restriction of both active and passive range of motion in the affected shoulder.

Significant limitation of shoulder external rotation compared with the contralateral side.

Ability to understand and follow verbal and visual instructions provided during the study.

Willingness to participate regularly in the six-week treatment program.

Voluntary participation in the study and provision of written informed consent.

Exclusion Criteria:

Presence of a full-thickness rotator cuff tear, advanced glenohumeral osteoarthritis, fracture, dislocation, or malignancy in the affected shoulder.

History of previous surgery involving the affected shoulder.

Cervical radiculopathy or other neurological disorders that may affect shoulder movements.

Presence of inflammatory rheumatic diseases.

Bilateral adhesive capsulitis.

History of injection therapy in the shoulder region within the previous three months.

Participation in another shoulder rehabilitation program during the study period.

Uncontrolled cardiovascular, neurological, or systemic diseases that may interfere with exercise participation.

Severe uncorrected visual impairment that prevents participants from viewing or following the non-immersive virtual reality application.

Cognitive impairment severe enough to interfere with communication or completion of assessment questionnaires.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Conventional Physiotherapy + Proprioceptive Neuromuscular Facilitation (PNF)

Participants in this group will receive conventional physiotherapy combined with traditional Proprioceptive Neuromuscular Facilitation (PNF) exercises. Each treatment session will last 60 minutes, consisting of 45 minutes of conventional physiotherapy and 15 minutes of therapist-guided PNF exercises. The PNF program will include upper extremity diagonal movement patterns (D1 and D2 flexion and extension). Treatment will be administered three times per week for six weeks, for a total of 18 sessions.

Participants will receive 45 minutes of conventional physiotherapy, including 15 minutes of superficial heat application, 15 minutes of transcutaneous electrical nerve stimulation (TENS), and 15 minutes of therapeutic exercises. Therapeutic exercises will include Codman pendulum exercises, active-assisted shoulder range of motion exercises, and stretching of the posterior shoulder capsule and pectoral muscles.

Following conventional physiotherapy, participants will perform 15 minutes of therapist-guided Proprioceptive Neuromuscular Facilitation (PNF) exercises involving upper extremity D1 and D2 flexion-extension diagonal patterns. Each diagonal pattern will be performed in two sets of 10 repetitions, with 30 seconds of rest between sets. Rhythmic initiation and progressive pain-free manual resistance will be applied according to individual tolerance.

Treatment will be administered three times per week for six weeks, totaling 18 sessions.

Experimental: Conventional Physiotherapy + Non-Immersive Virtual Reality-Assisted PNF

Participants in this group will receive conventional physiotherapy combined with non-immersive virtual reality-assisted Proprioceptive Neuromuscular Facilitation (PNF) exercises. Each treatment session will last 60 minutes, consisting of 45 minutes of conventional physiotherapy and 15 minutes of virtual reality-assisted PNF exercises. The exercises will involve upper extremity diagonal movement patterns (D1 and D2 flexion and extension) performed using a screen-based interactive system that provides real-time visual feedback. Treatment will be administered three times per week for six weeks, for a total of 18 sessions.

Participants will receive the same 45-minute conventional physiotherapy program, including 15 minutes of superficial heat application, 15 minutes of transcutaneous electrical nerve stimulation (TENS), and 15 minutes of therapeutic exercises consisting of Codman pendulum exercises, active-assisted shoulder range of motion exercises, and stretching exercises.

Following conventional physiotherapy, participants will perform 15 minutes of non-immersive virtual reality-assisted Proprioceptive Neuromuscular Facilitation (PNF) exercises. Upper extremity D1 and D2 flexion-extension diagonal movement patterns will be performed using a screen-based interactive virtual environment. A motion-tracking system will transfer upper extremity movements to virtual targets and provide real-time visual feedback regarding movement direction and completion.

Treatment will be administered three times per week for six weeks, totaling 18 sessions.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Shoulder Pain and Disability Index (SPADI) Total Score
Time Frame: 6 weeks

Shoulder-specific pain and disability will be assessed using the Shoulder Pain and Disability Index (SPADI). The SPADI consists of 13 items divided into two subscales: pain (5 items) and disability (8 items). Pain and disability subscale scores are calculated separately, and a total SPADI score is obtained. Scores range from 0 to 100, with higher scores indicating greater shoulder pain and functional disability. The primary outcome will be the change in the SPADI total score from baseline to the end of the six-week intervention.

6 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Pain Intensity Assessed by the Visual Analog Scale (VAS)
Time Frame: 6 weeks

Pain intensity will be assessed using the Visual Analog Scale (VAS) under three conditions: at rest, during activity, and at night. Participants will indicate their pain intensity experienced during the previous week on three separate 10-cm horizontal lines, ranging from 0 (no pain) to 10 (unbearable pain). The distance from the starting point to the marked position will be measured in centimeters. Higher scores indicate greater pain intensity. Changes in resting, activity-related, and nighttime pain will be evaluated separately from baseline to the end of the six-week intervention.

6 weeks
Change in Tampa Scale for Kinesiophobia (TSK) Total Score
Time Frame: 6 weeks

Kinesiophobia will be assessed using the Tampa Scale for Kinesiophobia (TSK), which measures fear of movement associated with pain or anticipated reinjury. The scale consists of 17 items, each scored from 1 (strongly disagree) to 4 (strongly agree). After reverse-scoring four items, the total score ranges from 17 to 68, with higher scores indicating greater fear of movement. Changes in the total TSK score will be assessed from baseline to the end of the six-week intervention.

6 weeks
Change in Disabilities of the Arm, Shoulder and Hand (DASH) Score
Time Frame: 6 week

Upper extremity function will be assessed using the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire. The DASH consists of 30 items evaluating difficulties in performing daily activities, limitations in social and occupational functioning, pain, and other upper extremity symptoms. Each item is scored from 1 to 5, and the total score is transformed to a scale ranging from 0 to 100. A score of 0 indicates no disability, while 100 indicates the greatest level of disability. Changes in the DASH score will be assessed from baseline to the end of the six-week intervention.

6 week
Change in Pain Catastrophizing Scale (PCS) Total Score
Time Frame: 6 weeks

Pain catastrophizing will be assessed using the Pain Catastrophizing Scale (PCS). The scale consists of 13 items divided into three subscales: rumination, magnification, and helplessness. Each item is scored from 0 (not at all) to 4 (all the time), resulting in a total score ranging from 0 to 52. Higher scores indicate greater levels of pain catastrophizing. Changes in the total PCS score will be assessed from baseline to the end of the six-week intervention.

6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Mehmet CANLI, PhD., Kirsehir Ahi Evran Universitesi

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 15, 2026

Primary Completion (Estimated)

May 1, 2027

Study Completion (Estimated)

May 15, 2027

Study Registration Dates

First Submitted

November 11, 2026

First Submitted That Met QC Criteria

November 11, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 43834581758%

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe